A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel

Part of paid clinical trials in Denver, Colorado.

Sponsor
Iovance Biotherapeutics, Inc.
Study ID
NCT06940739
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • IOV-3001 — BIOLOGICAL
    IOV-3001 will be administered as a single dose by IV infusion, which will be administered in a hospital setting.

Study Details

A Phase 1/2, open-label study of a modified interleukin-2 fusion protein (IOV 3001) in participants with previously treated, unresectable or metastatic melanoma who will receive lifileucel.

Key Dates

Start date
Mar 11, 2025
Status verified
May 2025
Primary completion
Jun 30, 2032
Completion
Jul 31, 2032

Study Design

Enrollment
42 participants (estimated)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
OTHER

Arms

  • Experimental: Assigned Interventions
    Dose escalation participants with unresectable or metastatic melanoma

Primary Outcome Measure

Safety and Tolerability [ Time Frame: Up to 30 days ]

Central Contacts

Locations (3)

FacilityCityStateZIPSite coordinators
SCRI Oncology Partners- DenverDenverColorado80218-
UNC Hospitals, The University of North Carolina at Chapel HillChapel HillNorth Carolina27514-
Sarah Cannon Research InstituteNashvilleTennessee37203-

Find similar trials in Denver, CO

By condition
Melanoma
By specialty
OncologySkin cancerDermatology
By research site
SCRI Oncology Partners- Denver· Denver, COUNC Hospitals, The University of North Carolina at Chapel Hill· Chapel Hill, NCSarah Cannon Research Institute· Nashville, TN

Related Studies